Emerging therapeutic targets for primary sclerosing cholangitis

References

• Karlsen TH, Folseraas T, Thorburn D, et al. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67(6):1298–1323.
   PubMed Web of Science ®Google Scholar
• Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003;125(5):1364–1369.
   PubMed Web of Science ®Google Scholar
• Chapman RW. High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology. 2009;50(3):671–673.
   PubMed Web of Science ®Google Scholar
• Gulamhusein AF, Eaton JE, Tabibian JH, et al. Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD. Am J Gastroenterol. 2016;111(5):705–711.
   PubMed Web of Science ®Google Scholar
• Ngu JH, Gearry RB, Wright AJ, et al. Inflammatory bowel disease is associated with poor outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9(12): 1092–1097. quiz e135.
   PubMed Web of Science ®Google Scholar
• Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79(2):200–206.
   PubMed Web of Science ®Google Scholar
• Bjoro K, Brandsaeter B, Foss A, et al. Liver transplantation in primary sclerosing cholangitis. Semin Liver Dis. 2006;26(1):69–79.
   PubMed Web of Science ®Google Scholar
• Gordon FD, Goldberg DS, Goodrich NP, et al. Recurrent primary sclerosing cholangitis in the adult-to-adult living donor liver transplantation cohort study: comparison of risk factors between living and deceased donor recipients. Liver Transpl. 2016;22(9):1214–1222.
   PubMed Web of Science ®Google Scholar
• Singal AK, Fang X, Kaif M, et al. Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation. Transpl International: Official Journal Eur Soc Transplant. 2017;30(5):454–462.
   PubMed Web of Science ®Google Scholar
• Rodriguez EA, Carey EJ, Lindor KD. Emerging treatments for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2017;11(5):451–459.
   PubMed Web of Science ®Google Scholar
• Hilscher M, Enders FB, Carey EJ, et al. Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis. Ann Hepatol. 2016;15(2):246–253.
   PubMed Web of Science ®Google Scholar
• Lindstrom L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11(7):841–846.
   PubMed Web of Science ®Google Scholar
• Stanich PP, Bjornsson E, Gossard AA, et al. Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis. Dig Liver Dis. 2011;43(4):309–313.
   PubMedGoogle Scholar
• Ponsioen CY, Chapman RW, Chazouilleres O, et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process. Hepatology. 2016;63(4):1357–1367.
   PubMed Web of Science ®Google Scholar
• Lindor KD. Ursodiol for primary sclerosing cholangitis ursodeoxycholic acid study group. mayo primary sclerosing cholangitis-ursodeoxycholic acid study group. N Engl J Med. 1997;336(10):691–695.
   PubMed Web of Science ®Google Scholar
• Chazouilleres O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990;11(1):120–123.
   PubMed Web of Science ®Google Scholar
• Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology. 1992;16(3):707–714.
   PubMed Web of Science ®Google Scholar
• Stiehl A, Walker S, Stiehl L, et al. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol. 1994;20(1):57–64.
   PubMed Web of Science ®Google Scholar
• Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology. 2005;129(5):1464–1472.
   PubMed Web of Science ®Google Scholar
• Harnois DM, Angulo P, Jorgensen RA, et al. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol. 2001;96(5):1558–1562.
   PubMed Web of Science ®Google Scholar
• Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol. 2008;48(5):792–800.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–814.
   PubMed Web of Science ®Google Scholar
• Triantos CK, Koukias NM, Nikolopoulou VN, et al. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2011;34(8):901–910.
   PubMed Web of Science ®Google Scholar
• Poropat G, Giljaca V, Stimac D, et al. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011;1:CD003626.
   PubMed Web of Science ®Google Scholar
• Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–678.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of L. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–267.
   PubMed Web of Science ®Google Scholar
• Wunsch E, Trottier J, Milkiewicz M, et al. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis. Hepatology. 2014;60(3):931–940.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Kowdley KV, Harrison ME. American College of G. ACG Clin Guideline. 2015;110(5):646–659.
   Google Scholar
• Tabibian JH, O’Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol. 2014;49(8):901–908.
   PubMed Web of Science ®Google Scholar
• Trauner M, Halilbasic E, Claudel T, et al. Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis. 2015;33(3):433–439.
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Fiorotto R, Fickert P, et al. Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology. 2009;49(6):1972–1981.
   PubMed Web of Science ®Google Scholar
• Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology. 2006;130(2):465–481.
   PubMed Web of Science ®Google Scholar
• Fickert P, Hirschfield GM, Denk G, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549–558.
   PubMed Web of Science ®Google Scholar
• Moustafa T, Fickert P, Magnes C, et al. Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. Gastroenterology. 2012;142(1):140–51 e12.
   PubMed Web of Science ®Google Scholar
• Oude Elferink RP, Ottenhoff R, van Wijland M, et al. Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest. 1995;95(1):31–38.
   PubMed Web of Science ®Google Scholar
• Ghonem NS, Assis DN, Boyer JL. Fibrates and cholestasis. Hepatology. 2015;62(2):635–643.
   PubMed Web of Science ®Google Scholar
• Kita R, Kita-Sasai Y, Hanaoka I, et al. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am J Gastroenterol. 2002;97(7):1849–1851.
   PubMed Web of Science ®Google Scholar
• Kita R, Takamatsu S, Kimura T, et al. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol. 2006;41(7):686–692.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Hirano K, Tada M, et al. Bezafibrate for the treatment of primary sclerosing cholangitis. J Gastroenterol. 2010;45(7):758–762.
   PubMed Web of Science ®Google Scholar
• Kurihara T, Maeda A, Shigemoto M, et al. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis. J Gastroenterol. 2003;38(3):300–301.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Hirano K, Isayama H, et al. Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2015;22(10):766–770.
   PubMed Web of Science ®Google Scholar
• Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol. 2015;110(3):423–431.
   PubMed Web of Science ®Google Scholar
• Miethke AG, Zhang W, Simmons J, et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology. 2016;63(2):512–523.
   PubMed Web of Science ®Google Scholar
• Baghdasaryan A, Chiba P, Trauner M. Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med. 2014;37:57–76.
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011;331(6024):1621–1624.
   PubMed Web of Science ®Google Scholar
• Axelson M, Aly A, Sjovall J. Levels of 7 alpha-hydroxy-4-cholesten-3-one in plasma reflect rates of bile acid synthesis in man. FEBS Letters. 1988;239(2):324–328.
   PubMed Web of Science ®Google Scholar
• Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4(6):391–417.
   PubMedGoogle Scholar
• Cai SY, He H, Nguyen T, et al. Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. J Lipid Res. 2010;51(8):2265–2274.
   PubMed Web of Science ®Google Scholar
• Reichrath J, Rech M, Moeini M, et al. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther. 2007;6(1):48–55.
   PubMed Web of Science ®Google Scholar
• Bruck R, Weiss S, Aeed H, et al. Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor. Dig Dis Sci. 2009;54(2):292–299.
   PubMed Web of Science ®Google Scholar
• Yu D, Cai SY, Mennone A, et al. Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents. Liver Int. 2018;38(6):1128–1138.
   PubMed Web of Science ®Google Scholar
• Levin AA, Sturzenbecker LJ, Kazmer S, et al. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha. Nature. 1992;355(6358):359–361.
   PubMed Web of Science ®Google Scholar
• He H, Mennone A, Boyer JL, et al. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011;53(2):548–557.
   PubMed Web of Science ®Google Scholar
• Cai SY, Mennone A, Soroka CJ, et al. All-trans-retinoic acid improves cholestasis in alpha-naphthylisothiocyanate-treated rats and Mdr2-/- mice. J Pharmacol Exp Ther. 2014;349(1):94–98.
   PubMed Web of Science ®Google Scholar
• Ali AH, Tabibian JH, Carey EJ, et al. Emerging drugs for the treatment of Primary Biliary Cholangitis. Expert Opin Emerg Drugs. 2016;21(1):39–56.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17):3569–3572.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–965.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751–61 e8.
   PubMed Web of Science ®Google Scholar
• Larusso NF, Bowlus CL, Levy C, et al. The AESOP trial: A randomized, double-blind, placebo-controlled, phase 2 tudy of obeticholic acid in patients with primary sclerosing cholangitis. Dig Liver Dis. 2018;50(2):Suppl. E67.
   Google Scholar
• Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009–1017.
   PubMed Web of Science ®Google Scholar
• Ikenega N, Peng ZW, Vaid KA, et al.  Selective targeting of lysyl oxidase-like 2(LOXL2) suppresses hepatic fibrosis and accelerates its reversal.  Gut. 2017;66:1540–1541.
   Google Scholar
• Vadasz Z, Kessler O, Akiri G, et al. Abnormal deposition of collagen around hepatocytes in Wilson’s disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol. 2005;43(3):499–507.
   PubMed Web of Science ®Google Scholar
• Williamson KD, Chapman RW. New Therapeutic Strategies for Primary Sclerosing Cholangitis. Semin Liver Dis. 2016;36(1):5–14.
   PubMed Web of Science ®Google Scholar
• Muir A, Goodman Z, Levy C, et al. Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose –ranging, randomized, placebo-controlled trial. J Hepatol. 2017;66:S73.
   Web of Science ®Google Scholar
• Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Reviews Immunol. 2006;6(3):244–251.
   PubMed Web of Science ®Google Scholar
• Eksteen B, Grant AJ, Miles A, et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med. 2004;200(11):1511–1517.
   PubMed Web of Science ®Google Scholar
• Keshav S, Vanasek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn’s disease. PloS One. 2013;8(3):e60094.
   PubMed Web of Science ®Google Scholar
• Arseneau KO, Cominelli F. Vercirnon for the treatment of Crohn’s disease. Expert Opin Investig Drugs. 2013;22(7):907–913.
   PubMed Web of Science ®Google Scholar
• Christensen B, Micic D, Gibson PR, et al. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018;47(6):753–762.
   PubMed Web of Science ®Google Scholar
• Pannecoeck R, Serruys D, Benmeridja L, et al. Vascular adhesion protein-1: role in human pathology and application as a biomarker. Crit Rev Clin Lab Sci. 2015;52(6):284–300.
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Tickle J, Vesterhus MN, et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut. 2018;67(6):1135–1145.
   PubMed Web of Science ®Google Scholar
• Marttila-Ichihara F, Smith DJ, Stolen C, et al. Vascular amine oxidases are needed for leukocyte extravasation into inflamed joints in vivo. Arthritis Rheum. 2006;54(9):2852–2862.
   PubMedGoogle Scholar
• Shields PL, Morland CM, Salmon M, et al. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunology. 1999;163(11):6236–6243.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, O’Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology. 2016;63(1):185–196.
   PubMed Web of Science ®Google Scholar
• Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota __ ___profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol. 2017;23(25):4548–4558.
   PubMed Web of Science ®Google Scholar
• Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamicsof the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, Boonstra K, et al. The mucosa-associated microbiota of PSC patients is characterized by low diversity and low abundance of uncultured Clostridiales II. J Crohns Colitis. 2015;9(4):342–348.
   PubMed Web of Science ®Google Scholar
• Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66(4):611–619.
   PubMed Web of Science ®Google Scholar
• Lichtman SN, Keku J, Schwab JH, et al. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology. 1991;100(2):513–519.
   PubMed Web of Science ®Google Scholar
• Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology. 2004;40(6):1379–1386.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol. 2009;104(1):83–88.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther. 2013;37(6):604–612.
   PubMed Web of Science ®Google Scholar
• Tabibian JH, Gossard A, El-Youssef M, et al. Prospective clinical trial of rifaximin therapy for patients with primary sclerosing cholangitis. Am J Ther. 2017;24(1):e56–e63.
   PubMed Web of Science ®Google Scholar
• Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. Jama. 2017;318(20):1985–1993.
   PubMed Web of Science ®Google Scholar
• Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65(10):1681–1689.
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Fuchs C, Hofer H, et al. Therapy of primary sclerosing cholangitis–today and tomorrow. Dig Dis. 2015;33(Suppl 2):149–163.
   PubMedGoogle Scholar
• Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur J Gastroenterol Hepatol. 2008;20(7):688–692.
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Lindqvist-Ottosson J, Asztely M, et al. Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2004;99(3):502–508.
   PubMed Web of Science ®Google Scholar
• Visrodia KH, Tabibian JH, Baron TH. Endoscopic management of benign biliary strictures. World J Gastrointest Endosc. 2015;7(11):1003–1013.
   PubMed Web of Science ®Google Scholar
• Stiehl A, Rudolph G, Kloters-Plachky P, et al. Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36(2):151–156.
   PubMed Web of Science ®Google Scholar
• Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study. Int J Hepatol. 1997;26(3):560–566.
   Google Scholar
• Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc. 2001;53(3):308–312.
   PubMed Web of Science ®Google Scholar
• Ponsioen CY, Lam K. van Milligen de Wit Aw, Huibregtse K,Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol. 1999;94(9):2403–2407.
   PubMed Web of Science ®Google Scholar
• van Milligen de Wit AW, Rauws EA, van Bracht J, et al. Lack of complications following short-term stent therapy for extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc. 1997;46(4):344–347.
   PubMed Web of Science ®Google Scholar
• Lee JG, Schutz SM, England RE, et al. Endoscopic therapy of sclerosing cholangitis. Hepatology. 1995;21(3):661–667.
   PubMed Web of Science ®Google Scholar
• Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol. 2001;96(4):1059–1066.
   PubMed Web of Science ®Google Scholar
• Djordjev. B, Kim JH. Different lethal effects of mitomycin c and actinomycin D during division cycle of hela cells. J Cell Biol. 1968;38(3):477-&.
   Web of Science ®Google Scholar
• Gruber-Rouh T, Schmitt C, Naguib NNN, et al. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. BMC Cancer. 2018;18(1):188.
   PubMedGoogle Scholar
• Niikawa M, Nakamura T, Nagase H. Effect of cotreatment of aspirin metabolites on mitomycin C-induced genotoxicity using the somatic mutation and recombination test in Drosophila melanogaster. Drug Chem Toxicol. 2006;29(4):379–396.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Jorgensen RA, Anderson ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol. 1996;91(3):511–515.
   PubMed Web of Science ®Google Scholar
• Sterling RK, Salvatori JJ, Luketic VA, et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther. 2004;20(9):943–949.
   PubMed Web of Science ®Google Scholar
• Nf L, Wiesner RH, Ludwig J, et al. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology. 1988;95(4):1036–1042.
   PubMed Web of Science ®Google Scholar
• Angulo P, Bharucha AE, Jorgensen RA, et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci. 1999;44(3):602–607.
   PubMed Web of Science ®Google Scholar
• Bharucha AE, Jorgensen R, Lichtman SN, et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(9):2338–2342.
   PubMed Web of Science ®Google Scholar
• Angulo P, MacCarty RL, Sylvestre PB, et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci. 2002;47(1):157–161.
   PubMed Web of Science ®Google Scholar
• Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 1994;106(2):494–499.
   PubMed Web of Science ®Google Scholar
• Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci. 2004;49(1):1–4.
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Angulo P, Keach JC, et al. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol. 2005;100(2):308–312.
   PubMed Web of Science ®Google Scholar
• Talwalkar JA, Gossard AA, Keach JC, et al. Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int. 2007;27(4):451–453.
   PubMed Web of Science ®Google Scholar
• Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol. 2008;42(5):522–526.
   PubMed Web of Science ®Google Scholar
• Lindor KD, Wiesner RH, Colwell LJ, et al. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol. 1991;86(1):57–61.
   PubMed Web of Science ®Google Scholar
• van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC study group. Am J Gastroenterol. 2000;95(8):2015–2022.
   PubMed Web of Science ®Google Scholar